Zacks: Brokerages Anticipate Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) Will Announce Earnings of -$0.34 Per Share


Share on StockTwits

Equities analysts expect Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) to announce ($0.34) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Entasis Therapeutics’ earnings. The lowest EPS estimate is ($0.38) and the highest is ($0.32). Entasis Therapeutics posted earnings per share of ($1.15) during the same quarter last year, which suggests a positive year over year growth rate of 70.4%. The company is scheduled to issue its next earnings results on Thursday, May 6th.

On average, analysts expect that Entasis Therapeutics will report full-year earnings of ($1.29) per share for the current fiscal year, with EPS estimates ranging from ($1.36) to ($1.21). For the next year, analysts anticipate that the firm will post earnings of ($1.45) per share, with EPS estimates ranging from ($1.95) to ($0.83). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Entasis Therapeutics.

Entasis Therapeutics (NASDAQ:ETTX) last posted its quarterly earnings data on Monday, March 22nd. The company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.39) by $0.26.

Separately, Zacks Investment Research lowered shares of Entasis Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, March 25th. One analyst has rated the stock with a sell rating and eight have given a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $6.13.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC increased its holdings in Entasis Therapeutics by 478.9% in the fourth quarter. Virtu Financial LLC now owns 146,128 shares of the company’s stock worth $361,000 after buying an additional 120,887 shares during the last quarter. Squarepoint Ops LLC acquired a new position in Entasis Therapeutics in the fourth quarter worth approximately $147,000. Jaffetilchin Investment Partners LLC acquired a new position in Entasis Therapeutics in the fourth quarter worth approximately $27,000. Renaissance Technologies LLC increased its holdings in Entasis Therapeutics by 110.3% in the fourth quarter. Renaissance Technologies LLC now owns 506,389 shares of the company’s stock worth $1,251,000 after buying an additional 265,548 shares during the last quarter. Finally, Pivotal bioVenture Partners Investment Advisor LLC acquired a new position in Entasis Therapeutics in the fourth quarter worth approximately $2,915,000. 27.55% of the stock is owned by institutional investors and hedge funds.

NASDAQ:ETTX opened at $2.05 on Monday. Entasis Therapeutics has a twelve month low of $1.58 and a twelve month high of $4.25. The company has a 50-day moving average of $2.63 and a 200-day moving average of $2.40. The firm has a market cap of $76.49 million, a price-to-earnings ratio of -0.61 and a beta of 2.10.

About Entasis Therapeutics

Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.

See Also: How do investors use RSI to grade stocks?

Get a free copy of the Zacks research report on Entasis Therapeutics (ETTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Entasis Therapeutics (NASDAQ:ETTX)

Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.